US subsidiaries of Fresenius Medical Care receive subpoenas

Fresenius Medical Care AG ("the Company") (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world's largest provider of Dialysis Products and Services, today announced that its wholly owned subsidiaries, Fresenius Medical Care Holdings, Inc. and Spectra Renal Management, received on October 26 subpoenas from the U.S. Department of Justice, Eastern District of New York. The subpoenas require production of a broad range of documents relating to the company's operations, with specific attention to documents relating to testing for parathyroid hormone (PTH) levels and vitamin D therapies.

The company will cooperate with the government's investigation.

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: "Fresenius Medical Care North America ("FMC-NA") has operated since 1999 with one of the leading compliance programs in the US healthcare industry. We are firmly committed to compliance; our rigorous compliance program involves ongoing evaluation of business operations, compliance training for all employees, and audits of laboratory and dialysis services programs. FMC-NA's compliance program and its compliance audits, are subject to review each year by an independent review organization, and FMC-NA reports the results to the Office of the Inspector General. We will seek to meet with representatives of the government to discuss the issues addressed in the subpoena and are optimistic that the controls imbedded in our compliance program will be well received."

Conference Call
For further explanation on this matter Fresenius Medical Care will hold a Conference Call to discuss this matter on October 28, 2004, at 3:00 pm CET / 9:00 am EST. The dial in number is +1-706-645-9185 (International and North American Caller). A replay of the conference call will be available shortly after the event on Fresenius Medical Care's web page www.fmc-ag.com.